Compare AU
Compare TBIL vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck 1-3 Month Us Treasury Bond ETF (TBIL) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
TBIL | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 3 | 65 |
Median incremental investment | $687.74 | $897.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,034.60 | $1,919.79 |
Average age group | > 35 | 26 - 35 |
Key Summary
TBIL | DRUG | |
|---|---|---|
Strategy | TBIL.AX was created on 2023-05-16 by VanEck. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 148.5m in AUM and 19 holdings. TBIL.AX invests in a portfolio of US dollar denominated Treasury Bills issued by the US Government with a maturity ranging from 1-3 months with the aim of providing investment returns (before fees and costs) that closely track the returns of the Index | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | United States Treasury Bills (10.92 %) United States Treasury Bills (9.03 %) United States Treasury Bills (8.00 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (76.17 %) Communication Services (33.53 %) Health Care (23.66 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.22 % | 0.57 % |
Key Summary
TBIL | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | Bloomberg 1-3 Month U.S. Treasury Bill Index - Benchmark TR Gross | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.22 % | 0.57 % |
Price | $52.06 | $7.27 |
Size | $145.723 million | $171.463 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.86 % | 1.89 % |
Market | ASX | ASX |
First listed date | 17/05/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
TBIL | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 3 | 65 |
Median incremental investment | $687.74 | $897.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,034.60 | $1,919.79 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
TBIL | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
TBIL | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |